ライフサイエンスコーパス: tetanus

1 immobilizing whole-body muscle contraction (tetanus).

2 ted head wound can be confused with cephalic tetanus.

3 asant odor and a possible heightened risk of tetanus.

4 or vaccination responses against measles and tetanus.

5 rogress in eliminating maternal and neonatal tetanus.

6 nknown number of mothers die every year from tetanus.

7 d, 1 year after the program using diphtheria-tetanus-5-component acellular pertussis-inactivated poli

8 s high for measles, rubella, diphtheria, and tetanus (91%-98%; 95% confidence interval [CI] 87%-99%);

9 Contrariwise, tetanus AB (non-brain-binding) were present in serum and

10 that delay in vaccines containing diphtheria-tetanus-acellular pertussis (DTaP) is associated with re

11 who received at least 3 doses of diphtheria-tetanus-acellular pertussis vaccine by the end of 15 mon

12 t cohorts that received different diphtheria-tetanus-acellular pertussis vaccines (DTaP) during child

13 : combination diphtheria vaccine (diphtheria-tetanus-acellular pertussis-inactivated poliovirus/Haemo

14 onsistent limb group received the diphtheria-tetanus-acellular pertussis-inactived polio-Haemophilus

15 Treatment for tetanus aims to control spasms and reduce cardiovascular

16 ck, eel discharges cause brief, immobilizing tetanus, allowing eels to swallow small prey almost imme

17 levels against pertussis toxin, diphtheria, tetanus and 6 of 10 pneumococcal serotypes varied betwee

18 ell numbers were not affected, nor were anti-tetanus and anti-measles immunoglobulin G levels.

19 pared hospitalization rates and responses to tetanus and Bacille Calmette-Guerin vaccines among HEU a

20 Clostridial neurotoxins, including tetanus and botulinum neurotoxins, generally target vert

21 CNTs) responsible for the paralytic diseases tetanus and botulism, respectively.

22 ts aged >/=65 years who received the Tdap or tetanus and diphtheria (Td) vaccine during 1 January 200

23 ly 97% of the population was seropositive to tetanus and diphtheria as defined by a protective serum

24 the population will remain protected against tetanus and diphtheria for >/=30 years without requiring

25 t the current adult vaccination schedule for tetanus and diphtheria should be revisited.

26 papillomavirus, meningococcal conjugate, and tetanus and diphtheria toxoids and acellular pertussis v

27 adult immunization schedules recommend that tetanus and diphtheria vaccination be performed every 10

28 ibody titers were 3.6 and 0.35 IU/mL against tetanus and diphtheria, respectively.

29 d stocking seasonal influenza; pneumococcal; tetanus and diphtheria; and tetanus, diphtheria, and ace

30 ment and had protective vaccine responses to tetanus and Haemophilus influenzae.

31 chieved protective thresholds; antibodies to tetanus and Hib were higher.

32 he tetanus toxoid present in the diphtheria, tetanus and pertussis (DTP) vaccine.

33 , and parenteral vaccines against pertussis, tetanus, and measles in an observational study that moni

34 e platform for integrating measles, neonatal tetanus, and other vaccine-preventable disease surveilla

35 to examine trends in coverage of diphtheria, tetanus, and pertussis (DTP) vaccination across 190 coun

36 ird dose of a vaccine containing diphtheria, tetanus, and pertussis antigens (DTP3) was >/=90% in 14

37 o had received the third dose of diphtheria, tetanus, and pertussis vaccine were randomly assigned to

38 mary course only (three doses of diphtheria, tetanus, and pertussis vaccines [DTP3] commencing in 198

39 entavalent vaccine (which covers diphtheria, tetanus, and whole-cell pertussis; hepatitis B; and Haem

40 lateral flow immunochromatographic assay for tetanus antibodies.

41 1 million cases of tetanus are estimated to occur worldwide each year, with

42 pothesis that improved community immunity to tetanus as a result of the PsA-TT campaigns may be havin

43 opment of therapeutics for the prevention of tetanus by targeting this protein-protein interaction.

44 Tetanus can present with unusual clinical forms; therefo

45 Few associations were observed for anti-tetanus concentrations.

46 st that relatively recent receipt of a prior tetanus-containing vaccination does not increase risk af

47 birth outcomes related to timing since prior tetanus-containing vaccination.

48 received Tdap in pregnancy following a prior tetanus-containing vaccine less than 2 years before, 2 t

49 nated with Tdap in pregnancy and had a prior tetanus-containing vaccine more than 5 years before serv

50 al muscle sarcomeres during relaxation after tetanus contraction.

51 2+) concentrations in the case of twitch and tetanus, corresponding to different applied currents.

52 Antibody responses to tetanus declined with an estimated half-life of 14 years

53 interval compared to the prior 12 months for tetanus diphtheria combination, 23-valent pneumococcal p

54 re randomized to receive III-TT conjugate or tetanus diphtheria toxoid vaccine in a multicenter, obse

55 The effect a maternal tetanus, diphtheria, acellular pertussis (Tdap) vaccine

56 onths after delivery in women immunized with tetanus, diphtheria, and acellular pertussis (Tdap) afte

57 All US women are recommended to receive a tetanus, diphtheria, and acellular pertussis (Tdap) vacc

58 nvestigated the association between prenatal tetanus, diphtheria, and acellular pertussis (Tdap) vacc

59 term infants born to mothers vaccinated with tetanus, diphtheria, and acellular pertussis (Tdap) vacc

60 Immunization Practices (ACIP) recommends the tetanus, diphtheria, and acellular pertussis (Tdap) vacc

61 Women are recommended to receive tetanus, diphtheria, and acellular pertussis (Tdap) vacc

62 several countries have recommended universal tetanus, diphtheria, and acellular pertussis immunisatio

63 a; pneumococcal; tetanus and diphtheria; and tetanus, diphtheria, and acellular pertussis vaccines.

64 Thirty infants of Tdap (tetanus, diphtheria, and acellular pertussis)-vaccinated

65 uch as exposure to pyriproxyfen or vaccines (tetanus, diphtheria, and acellular pertussis, measles an

66 Therefore, an additional tetanus-diphtheria campaign may be warranted in MSs to a

67 tous hemagglutinin (FHA) coadministered with tetanus-diphtheria toxoids (Td), compared to a licensed

68 ter (GW 13-25) vs third-trimester (>/=GW 26) tetanus-diphtheria-acellular pertussis (Tdap) immunizati

69 sis mortality in high-income countries using tetanus-diphtheria-acellular pertussis (Tdap) vaccines i

70 term infants born to mothers vaccinated with tetanus-diphtheria-acellular pertussis (Tdap)-vaccine du

71 estimated the vaccine effectiveness (VE) of tetanus-diphtheria-acellular pertussis vaccine (Tdap) fo

72 Published data on the safety of tetanus-diphtheria-acellular pertussis vaccine (Tdap) in

73 htheria toxoids (Td), compared to a licensed tetanus-diphtheria-aP vaccine containing chemically deto

74 ve either BCG, followed by a booster dose of tetanus-diphtheria-pertussis inactivated polio vaccine (

75 vaccination (IIV3) at enrollment, and either tetanus-diphtheria-pertussis vaccination or IIV3 6 month

76 ne site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve

77 anuary 2012, the scheduled administration of tetanus/diphtheria/acellular pertussis and meningococcal

78 esolution (5 x 5 km) of diphtheria-pertussis-tetanus (DPT) vaccine coverage and dropout for children

79 the characteristic paralyses of botulism and tetanus during bacterial infection.

80 No pre-/post-tetanus effects were found in either subject group for t

81 The Maternal and Neonatal Tetanus Elimination Initiative, launched by WHO and its

82 the NMDA receptor-mediated component of the tetanus-evoked responses.

83 Neonatal cases of tetanus fell by 25% in countries that completed PsA-TT c

84 in (FHA), fimbriae 2 + 3 (FIMs), diphtheria, tetanus, Hib, MCC and PCV13 serotypes were compared to r

85 igens), as well as to other pathogens beyond tetanus, highlighting the usefulness of this technique t

86 r vaccination with PsA-TT effectively boosts tetanus immunity in a population with heterogeneous base

87 in a population with heterogeneous baseline tetanus immunity is not known.

88 t vaccines because of their ability to boost tetanus immunity.

89 We report a case of generalised tetanus in a 22-year-old woman that arose despite the pr

90 aving an impact on the incidence of neonatal tetanus in sub-Saharan Africa.

91 ed Ca(2+) release event by either a synaptic tetanus in the presence of 3-((R)-2-carboxypiperazine-4-

92 the prey's location and eliciting the full, tetanus-inducing volley.

93 The success of tetanus, influenza, and pertussis immunisation during pr

94 Tetanus is a life-threatening but preventable disease ca

95 Tetanus is a vaccine-preventable disease that still comm

96 Tetanus is almost completely preventable by active immun

97 Maternal and neonatal tetanus is still a substantial but preventable cause of

98 nd, antenatal pertussis immunization using a tetanus/low-dose diphtheria/5-component acellular-pertus

99 on programs to prevent maternal and neonatal tetanus, maternal immunization has been well received in

100 Tetanus neurotoxin (TeNT) and botulinum neurotoxin (BoNT

101 Botulinum neurotoxins (BoNTs) and tetanus neurotoxin (TeNT) are the most potent toxins kno

102 Tetanus neurotoxin (TeNT) causes neuroparalytic disease

103 timulation, which was enhanced by expressing tetanus neurotoxin (TeNT) in the ipsilateral axon, to pr

104 Tetanus neurotoxin (TeNT) is among the most poisonous su

105 not v-SNAREs (synaptobrevins/VAMP1/2/3 using tetanus neurotoxin (TeNT), also in TI-VAMP/VAMP7 knock-o

106 ch include botulinum neurotoxins (BoNTs) and tetanus neurotoxin (TeNT), are the most potent toxins kn

107 t RSK2 and PLD1 positively control fusion of tetanus neurotoxin insensitive vesicle-associated membra

108 al for spontaneous recovery after stroke, as tetanus neurotoxin silencing specifically of the SVZ-der

109 ed vectors were co-transported with both the tetanus neurotoxin-binding fragment and the membrane pro

110 Botulinum and tetanus neurotoxins, which specifically proteolyze vesic

111 en and 37 infants of women vaccinated with a tetanus-only vaccine received a fourth aP-containing vac

112 alently attached to protein carriers such as tetanus or diphtheria toxoids.

113 proved coverage in three doses of diphtheria tetanus pertussis containing vaccine between 2013 and 20

114 (routine), such as the standard diphtheria, tetanus, pertussis (DTP)-containing vaccine.

115 ly new strategy, and is currently limited to tetanus, pertussis, and influenza vaccines.

116 han controls against pneumococcal serotypes, tetanus, pertussis, and varicella despite previous vacci

117 ve OPV with pentavalent vaccine (diphtheria, tetanus, pertussis, Haemophilus influenzae type b, and h

118 nt vaccines: polio, pentavalent (diphtheria, tetanus, pertussis, hepatitis B virus, and Haemophilus i

119 es of childhood immunisation for diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae

120 munogenicity of postchemotherapy diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus

121 Plasma IgG levels specific for diphtheria, tetanus, pertussis, measles, rubella, and Haemophilus in

122 was inactivated vaccine against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae ty

123 ortality has been described after diphtheria-tetanus-pertussis (DTP) vaccination in females.

124 nfants' antibody responses to the diphtheria-tetanus-pertussis (DTP) vaccine included in the Expanded

125 o-administered with either BCG or diphtheria-tetanus-pertussis (DTP)1; and the second or third dose w

126 delivery at the time of the first diphtheria-tetanus-pertussis vaccine (DTP1) or the first measles-co

127 d coverage with the third dose of diphtheria-tetanus-pertussis vaccine (DTP3) to district-reported co

128 he routine immunization schedule: diphtheria-tetanus-pertussis vaccine dose 1 (DTP1), DTP2, DTP3, and

129 f Immunisation (eg, BCG, measles, diphtheria-tetanus-pertussis, and three doses of polio) doubled ove

130 of annual national third dose of diphtheria-tetanus-pertussis-containing vaccine (DTP3) and third do

131 ual improvement in third dose of diphtheria- tetanus-pertussis-containing vaccine (DTP3) coverage in

132 the coverage of the third dose of diphtheria-tetanus-pertussis-containing vaccine (DTP3), which is ty

133 cillus Calmette-Guerin, diphtheria-pertussis-tetanus, polio, and maternal tetanus vaccinations.

134 hort-term homosynaptic plasticity induced by tetanus [post-tetanic potentiation (PTP)] or low-frequen

135 finding that LTP induced by prolonged theta tetanus (PTT-LTP) depends on Cav1.2 and its regulation b

136 ximal stress: 11 +/- 1 ms) and a high twitch/tetanus ratio (0.91 +/- 0.05), indicating adaptations fo

137 accine except for Tdap (adolescent and adult tetanus, reduced diphtheria, acellular pertussis) vaccin

138 Maternal vaccination with tetanus, reduced-dose diphtheria, and acellular pertussi

139 ss to mechanical ventilation, mortality from tetanus remains high.

140 and are the causative agents of botulism and tetanus, respectively.

141 t potent toxins known and cause botulism and tetanus, respectively.

142 PsA-TT generated robust tetanus serologic responses in 1- to 29-year-olds, simil

143 in Africa assessed whether PsA-TT generated tetanus serologic responses when tested in African popul

144 Tetanus seroprevalence was similar among 1- to 6-year-ol

145 inding, whereas positive-control staining of tetanus-specific CD4 T cells was routinely successful.

146 tered MBC subset distributions, detection of tetanus-specific MBC from cord blood, indicative of feta

147 o significantly increased basal, twitch, and tetanus stresses, as measured using the Muscular Thin Fi

148 toxic CD8 T-cell epitope from CMV pp65 and a tetanus T-helper epitope.

149 In addition, slow muscle twitch, tetanus tension, and susceptibility to injury were all s

150 After the tetanus, the released heads slowly recover toward the re

151 ocampal pyramidal neurons that occurs during tetanus, thus opposing the induction of synaptic plastic

152 Mean anti-tetanus titres were 3.4% (0.19-6.5; p = 0.038) higher in

153 Mean anti-tetanus titres were higher by 9.0% (5.5-12.5), 7.8% (4.3

154 Botulinum neurotoxins (BoNTs) and tetanus toxin (TeNT) are the most potent toxins for huma

155 n by different neuronal subtypes, we express tetanus toxin (TeNT) in individual reticulospinal or CoP

156 Six rats received injections of tetanus toxin (TeTX) in the ventral hippocampus that res

157 nditional expression of the light chain from tetanus toxin (tox) in raphe neurons expressing serotone

158 ptic transmission of select PVT neurons with tetanus toxin activated via retrograde trans-synaptic tr

159 Furthermore, B-cell responses to tetanus toxin but not influenza hemagglutinin in the ART

160 Here, we show that ensilication stabilizes tetanus toxin C fragment (TTCF), a component of the teta

161 We find that the axons of individual tetanus toxin expressing reticulospinal neurons have few

162 bition of vesicle release with cell-specific tetanus toxin expression results in pioneer axon pathfin

163 mpletely blocking synaptic transmission with tetanus toxin in cerebellar nuclei, which also reversed

164 egion- and cell-type-selective expression of tetanus toxin light chain (TeLC) and compared the functi

165 ition of GPe-projecting CeA neurons with the tetanus toxin light chain (TeLC) completely blocks audit

166 Silencing BPNs with tetanus toxin light chain (TeNT) increases bilateral mas

167 or targeted astrocyte-specific expression of tetanus toxin light chain (to interfere with vesicular r

168 f serotonergic and raphe neurons in mice for tetanus toxin light chain expression, which prevented ve

169 an adenoviral vector to specifically express tetanus toxin light chain in astrocytes) reduced the HVR

170 using Cre-inducible viral expression of the tetanus toxin light chain in male and female PV-Cre mice

171 culum by injecting a viral vector expressing tetanus toxin light chain in male mice.

172 ing the activity of the Ib or Is neuron with tetanus toxin light chain resulted in structural changes

173 nergic neurons, we inactivated them with the tetanus toxin light chain, a genetically encoded inhibit

174 , unc-1(dn) has effects opposite to those of tetanus toxin light chain, separating the roles of ADL e

175 dorant stimuli, optogenetics, and transgenic tetanus toxin neurotransmission block show that elevated

176 Expression of tetanus toxin to cleave VAMP2 in VAMP8 knock-out (-/-) a

177 ely, blocking glutamate release by targeting tetanus toxin to individual synapses increases alpha7-nA

178 p53, HER2-ICD, HER2-ECD, and CEA, but not to tetanus toxin, relative to controls and surgically resec

179 rom the cucumber mosaic virus containing the tetanus toxin-derived universal T-cell epitope tt830-843

180 ced TNF exocytosis in BMMCs was dependent on tetanus toxin-insensitive vesicle-associated membrane pr

181 In stark contrast, myelination along tetanus-toxin-expressing CoPA neuron axons is entirely n

182 made with the HMW polysaccharide coupled to tetanus toxoid (HMW-TT) conferred better protection agai

183 d to the minimal domain of the C fragment of tetanus toxoid (referred to herein as Tem1-TT vaccine).

184 neumococcal serotypes, pertussis toxin (PT), tetanus toxoid (TT) and varicella, and immunogenicity of

185 eningococcal conjugate vaccine, PsA-TT, uses tetanus toxoid (TT) as a carrier protein (PsA-TT).

186 gG and B-cell receptor repertoires following tetanus toxoid (TT) booster vaccination.

187 mmunization of mice with an optimized heroin-tetanus toxoid (TT) conjugate formulated with adjuvants

188 We assessed the impact of PsA-TT on tetanus toxoid (TT) immunity by quantifying age- and sex

189 (+) T cells that proliferated in response to tetanus toxoid (TT) presented by autologous CD B cells.

190 oconjugate made by conjugating this with the tetanus toxoid (TT) protein have been characterized and

191 polysaccharides, and very different from the tetanus toxoid (TT) protein used for the conjugation.

192 MV infection or were recently immunized with tetanus toxoid (TT) were included as controls.

193 CFSE-labeled PBMCs were stimulated with CMV, tetanus toxoid (TT), and C albicans antigens and subsequ

194 entous hemagglutinin (FHA), pertactin (Prn), tetanus toxoid (TT), and diphtheria toxoid (DT) were mea

195 y normal human mononuclear cells, induced by tetanus toxoid (TT), human thyroglobulin (TG), Escherich

196 encapsulation of two antigens, ovalbumin and tetanus toxoid (TT), in PLGA microspheres was adjusted b

197 D4(+) T cells via a carrier protein, such as tetanus toxoid (TT), resulting in the induction of PS-sp

198 C meningococcal polysaccharides, as well as tetanus toxoid (TT), was used to investigate the BCR rep

199 Tetanus toxoid (TT)-specific antibody avidity was increa

200 HIV-1 envelope glycoprotein (CN54gp140) and tetanus toxoid (TT).

201 ontrol mice at the time of immunization with tetanus toxoid adsorbed to aluminum hydroxide (TT/Alum).

202 ast Sweden cohort, were stimulated with Ags (tetanus toxoid and beta-lactoglobulin) and diabetes-rela

203 donors to retrieve human antibodies against tetanus toxoid and influenza hemagglutinin (HA) from H1N

204 Hapten 1 was conjugated to tetanus toxoid and mixed with liposomes containing monop

205 investigated in in vitro cocultures by using tetanus toxoid and Salmonella species as antigen models.

206 is profile also improved immune responses to tetanus toxoid and subunit influenza vaccine but not, a

207 Anti-tetanus toxoid antibody IgG geometric mean concentration

208 n of the group A polysaccharide and used its tetanus toxoid as the carrier protein to produce the now

209 ningococcal conjugate vaccine that used SIIL tetanus toxoid as the carrier protein.

210 , B cells and moDCs were pulsed with IgE-NIP-tetanus toxoid complexes and cocultured with autologous

211 A GBS type III capsular polysaccharide (CPS)-tetanus toxoid conjugate (III-TT) vaccine was evaluated

212 s incorporated into the original beta-mannan tetanus toxoid conjugate providing a tricomponent conjug

213 cine against Candida albicans, a beta-mannan tetanus toxoid conjugate showed poor immunogenicity in m

214 and capsular group C Neisseria meningitidis tetanus toxoid conjugate vaccine (Hib-MenC-TT), administ

215 A serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) wa

216 V is a single-dose typhoid Vi polysaccharide-tetanus toxoid conjugate vaccine for persons >/=6 months

217 y determined the effectiveness of a fentanyl-tetanus toxoid conjugate vaccine to alter fentanyl self-

218 wledge gap, we assessed the efficacy of a Vi-tetanus toxoid conjugate vaccine using an established hu

219 ia meningitidis group A (NmA) polysaccharide-tetanus toxoid conjugate vaccine, PsA-TT (MenAfriVac), d

220 A monovalent MenA polysaccharide-tetanus toxoid conjugate was therefore developed.

221 C-PS, a TI Ag, or a conjugate of MenC-PS and tetanus toxoid elicited an augmented PS-specific IgG res

222 t the preclinical development of recombinant tetanus toxoid heavy chain fragment (rTTHC) linked to FP

223 ells, peripheral plasmablasts isolated after tetanus toxoid immunization and memory B cells isolated

224 ent conjugate of (poly)glycerolphosphate and tetanus toxoid in alum plus CpG-oligodeoxynucleotides pr

225 ific for epitopes of HCMV phosphoprotein-65, tetanus toxoid precursor, EBV nuclear Ag 2, or HIV gag p

226 toxin C fragment (TTCF), a component of the tetanus toxoid present in the diphtheria, tetanus and pe

227 iour and unlike the previously characterised tetanus toxoid protein (slightly extended and hydrodynam

228 th a then-new meningococcal A polysaccharide-tetanus toxoid protein conjugate vaccine (PsA-TT, or Men

229 d testing of the newly WHO-prequalified ViPS-tetanus toxoid protein conjugate vaccine, providing effi

230 Conjugation with tetanus toxoid protein however greatly increased the mol

231 articular, MUC1 glycopeptide conjugates with Tetanus toxoid proved to be efficient vaccines inducing

232 erythrocytes, vaccinia virus, rotavirus, or tetanus toxoid provides evidence for reactivation of ane

233 ociated with increased IL-2 expression after tetanus toxoid stimulation.

234 ll responses against autoantigen or repeated tetanus toxoid stimulations require both Kv1.3 and KCa3.

235 g cells we measure in mice immunized against Tetanus Toxoid under largely varying conditions (antigen

236 ived from cucumber mosaic virus containing a tetanus toxoid universal T-cell epitope (CuMVTT).

237 aluminum phosphate, a commercially available tetanus toxoid vaccine adjuvanted with potassium alum, a

238 Moreover, topical delivery of tetanus toxoid vaccine to mice using STAR particles gene

239 erated after immunizations with conventional tetanus toxoid vaccine, and (2) preventing pathological

240 ricomponent vaccine, but not the beta-mannan tetanus toxoid vaccine, showed activation of BMDCs.

241 ur cells in culture, while MUC1 glycopeptide-Tetanus toxoid vaccines elicited antibodies in mice whic

242 omain (ICD), HER2-ECD, p53, IGFBP2, CEA, and tetanus toxoid were examined.

243 Pf merozoite surface protein-1 (MSP-1), and tetanus toxoid were measured by indirect enzyme-linked i

244 ation with irradiated anti-RNP (but not anti-tetanus toxoid) CD4(+) cells induced remission of anti-R

245 eonatal immunization with diphtheria toxoid, tetanus toxoid, and acellular pertussis vaccine has been

246 Currently inactivated influenza, tetanus toxoid, and acellular pertussis vaccines are rec

247 xoid cross-reactive material (CRM) 197 (DT), tetanus toxoid, and BSA, and combined with an adjuvant,

248 e prepared by coupling S. suis type 2 CPS to tetanus toxoid, and the immunological features of the po

249 < 0.01) but an increased immune response to tetanus toxoid, beta-lactoglobulin, and the autoantigens

250 tomegalovirus-pp65 (immunodominant protein), tetanus toxoid, measles, mumps, and rubella.

251 to recall Ags (purified protein derivative, Tetanus toxoid, or flu/EBV/CMV viral mix) in LN, despite

252 In response, a dose of tetanus toxoid, reduced diphtheria toxoid, and acellular

253 fant contact, receive a single dose of Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular

254 Maternal immunization with tetanus toxoid, reduced diphtheria toxoid, and acellular

255 ia Department of Health recommended that the tetanus toxoid, reduced diphtheria toxoid, and acellular

256 endation that all pregnant women receive the tetanus toxoid, reduced diphtheria toxoid, and acellular

257 In 2012, Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular

258 les for certain vaccines (eg, meningococcal; tetanus toxoid, reduced diphtheria toxoid, and reduced a

259 plasmablast reactivity to a control antigen, tetanus toxoid, was minimal and similar in all groups.

260 oped hybrid TT-OVA-PeptiCRAd containing both tetanus toxoid- and tumor-specific peptides.

261 ion of monocyte-derived dendritic cells, and tetanus toxoid-induced PBMC proliferation were assessed

262 Testing the distribution of tetanus toxoid-specific (TT(+)) mBCs revealed their pres

263 study the phenotype and frequency of D- and tetanus toxoid-specific B cells by culturing B cells in

264 Consistently, the avidity of tetanus toxoid-specific serum antibodies was substantial

265 immunisation coverage of pregnant women with tetanus toxoid.

266 red with other HIV antigens (such as p24) or tetanus toxoid.

267 ence in the increases in antibody binding to tetanus toxoid.

268 of interferon-gamma, after stimulation with tetanus toxoid.

269 of 4 vaccines: Vi-polysaccharide (Vi-PS), Vi-tetanus-toxoid conjugate vaccine (Vi-TT), live oral Ty21

270 djusted OR: 0.37; 95% CI 0.21-0.64) and with tetanus toxoidIgG3 levels equal or higher than the mean

271 safety study of a combination diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP),

272 estational age and receipt of diphtheria and tetanus toxoids and acellular pertussis vaccine.

273 lescent/adult formulations of diphtheria and tetanus toxoids and acellular pertussis, pneumococcal co

274 %) had received >/=3 doses of diphtheria and tetanus toxoids and aP vaccine at the time of their firs

275 Undervaccination for the diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine.

276 Three primary doses of the diphtheria-tetanus toxoids-acellular pertussis-inactivated poliomye

277 muno-agent along with a pertussis-diphtheria-tetanus triple vaccine for autoimmune CP/CPPS developmen

278 maternal vaccine and to those conjugated to tetanus (TT) or the diphtheria toxin variant, CRM.

279 on against measles, rubella, diphtheria, and tetanus, using Luminex multiplex bead assay (MBA).

280 various B cell subsets, and fetal priming to tetanus vaccination in cord blood from human United Stat

281 P) that developed shortly after a diphtheria tetanus vaccination is described, with a review of the l

282 ment of acute MMP shortly after a diphtheria tetanus vaccination may have been serendipitous, a resul

283 a pertussis and diphtheria component to the tetanus vaccination program in pregnant women in Vietnam

284 d vaccination, and in particular measles and tetanus vaccination, is associated with substantial redu

285 erosions 2 days after receiving a diphtheria tetanus vaccination.

286 heria-pertussis-tetanus, polio, and maternal tetanus vaccinations.

287 d second doses of diphtheria, pertussis, and tetanus vaccine (ie, 6 and 10 weeks of age, respectively

288 cord blood, indicative of fetal priming with tetanus vaccine given to pregnant women, was comparable

289 verage with 3rd dose of diphtheria-pertussis-tetanus vaccine in the 107 high-risk LGAs improved from

290 ion and decreased memory T-cell responses to tetanus vaccine were associated with HIV exposure and in

291 Mice preimmunized with tetanus vaccine were challenged with B16.OVA tumors and

292 Cephalic tetanus was initially suspected but laboratory testing c

293 The incidence of tetanus was probably decreased by giving millions of dos

294 No subjective sensation of involuntary tetanus was reported, and aversive sensations were restr

295 ASs and of antibodies against diphtheria and tetanus were measured and were compared with data from t

296 Incidence data for neonatal tetanus were reviewed for countries with and without PsA

297 ccinations against diphtheria, pertussis and tetanus, which contained gelatin as a stabilizer.

298 ng term potentiation induced by a 5-Hz/180-s tetanus, which mimics the endogenous theta-rhythm and de

299 e who had only received 1 dose of Diphtheria Tetanus whole cell Pertussis (DTwP).

300 and death, as described following diphtheria-tetanus-whole cell pertussis (DTP) vaccination.